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Abstract  1 
Background: Allogeneic hematopoietic cell transplantation (HCT) is often 2 
associated with poor oral intake due to painful mucositis and gastrointestinal 3 
sequalae that occur following a preparative regimen of intensive chemotherapy and/ 4 
or total body radiation. Although attractive to assume that optimal nutrition improves 5 
HCT outcomes, there are limited data to support this. It is also unclear whether 6 
artificial nutrition support should be provided as enteral tube feeding or parenteral 7 
nutrition (PN).  8 
Methods: We analysed day-100 non-relapse mortality (NRM), incidence of acute 9 
graft-versus-host disease (GvHD), acute gastrointestinal GvHD, 5-year survival and 10 
GvHD-free/relapse-free survival (GRFS) according to both route and adequacy of 11 
nutritional intake prior to neutrophil engraftment, together with other known 12 
prognostic factors, in a retrospective cohort of 484 patients who underwent 13 
allogeneic HCT for hematologic malignancy between 2000 and 2014.  14 
Results: Multivariate analyses showed increased NRM with inadequate nutrition 15 
(hazard ratio (HR) 4.1; 95% confidence interval (CI) 2.2–7.2) and adequate PN (HR 16 
2.9; 95% CI 1.6–5.4) compared to adequate enteral nutrition (EN) both P<.001. 17 
There were increased incidences of gastrointestinal GvHD of any stage and all 18 
GvHD ≥ grade 2 in patients who received PN (odds ratio (OR) 2.0; 95% CI 1.2–3.3; 19 
P=.006, and OR 1.8; 95% CI 1.1–3.0; P=.018, respectively), compared to adequate 20 
EN. Patients who received adequate PN and inadequate nutrition also had reduced 21 
probabilities of survival and GRFS at 5 years.  22 
Conclusion: Adequate EN during the early transplantation course is associated with 23 
reduced NRM, improved survival and GRFS at 5 years. Furthermore, adequate EN 24 
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is associated with lower incidence of overall and gut acute GvHD than PN, perhaps 25 
because of its ability to maintain mucosal integrity, modulate the immune response 26 
to intensive chemo/radiotherapy and support the gastrointestinal tract environment, 27 
including gut microflora. 28 
 29 
Key words: Allogeneic stem cell transplant, survival, graft-versus-host-disease, 30 
enteral nutrition, parenteral nutrition, non-relapse mortality, hematologic malignancy, 31 
artificial nutrition support. 32 
 33 
Introduction 34 
The side effects of allogeneic (donor) hematopoietic cell transplantation (HCT) 35 
frequently impair the ability of patients to consume an adequate diet. Patients 36 
receive intensive conditioning that may include high dose chemotherapy with or 37 
without total body irradiation, that can result in significant mucositis and other 38 
gastrointestinal sequelae. Oral intake declines rapidly in the first eight days after 39 
HCT and many patients consume less than 60% of their estimated energy 40 
requirements during this time (1). As a result nutritional status declines from 41 
transplant admission to discharge and this does not fully recover when assessed 42 
soon after discharge (2).  43 
Although it might seem obvious that optimal nutrition is likely to improve outcomes of 44 
HCT, the data to support this are extremely limited. The best way in which to support 45 
the nutritional intake of HCT recipients is also unclear. Some patients are able to 46 
maintain an adequate nutrient intake by consuming a diet higher in energy and 47 
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protein. However, for some, particularly those receiving myeloablative conditioning, 48 
artificial nutrition support (ANS) will be required. Historically, parenteral nutrition (PN) 49 
has been widely used in transplant recipients experiencing significant gastrointestinal 50 
toxicities. It is well established that oral intake and enteral tube feeding (ETF) are 51 
more physiological and associated with less metabolic and infectious risks than PN. 52 
Moreover there may be particular benefits of EN for the HCT recipient, via 53 
maintenance of gut mucosal integrity and in supporting the gastrointestinal tract 54 
environment, including gut microflora, that can be impaired during HCT (3;4) 55 
Alterations in gut microflora have recently been implicated in the development of 56 
graft versus host disease (GvHD) (5-7), which is associated with significant morbidity 57 
and mortality following donor HCT.  58 
In this study we analysed day-100 non-relapse mortality (NRM), incidence of acute 59 
graft-versus-host disease (GvHD) of any site, acute GvHD of the gastrointestinal 60 
tract, 5-year survival and GvHD-free/relapse-free survival (GRFS) after HCT 61 
according to both the route and adequacy of nutritional intake using a cohort of 62 
consecutive patients who underwent allogeneic HCT from a peripheral blood or bone 63 
marrow donor in a single institution. 64 
 65 
Subjects and methods 66 
Study cohort 67 
All patients aged 17 or above who underwent their first HCT for hematologic 68 
malignancy at Hammersmith Hospital, using a sibling or unrelated donor between 69 
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January 2000 and December 2014 were eligible. Umbilical cord blood transplants 70 
and HLA haploidentical transplants were excluded.  71 
Ethics 72 
All patients were treated on institutional review board–approved protocols or 73 
standard treatment protocols and gave consent in accordance with the Declaration of 74 
Helsinki of 1975 as revised in 1983. 75 
Nutritional support 76 
At our centre, all allogeneic HCT patients are routinely reviewed early in their 77 
transplant admission by a specialist dietitian as a standard of their transplant care. 78 
All patients receiving myeloablative regimens are advised to have an enteral feeding 79 
tube inserted routinely after establishing good control of the emetogenic effects of 80 
the conditioning regimen and prior to development of mucositis. Any patient 81 
experiencing symptoms that impact their oral intake are referred by nursing and 82 
medical staff for more regular assessment by the specialist dietitian. Nutritional 83 
status is assessed from daily measurements of weight and body mass index (BMI) 84 
relative to pre-treatment weights. Adjusted dry weights are estimated (8) when signs 85 
of fluid accumulation are evident clinically or if there are unlikely short term weight 86 
gains. Energy and protein requirements are estimated using predictive formulae 87 
based on age, gender, physical activity and metabolic factors (9-11).  88 
In all patients the criteria for initiation of ANS are: (a) patients’ actual or anticipated 89 
oral intake below 1/3 of estimated requirements for 5 days or below 2/3 of estimated 90 
requirements for 10 days, (b) if 10% weight loss of pre-transplant weight, or (c) 91 
where significant weight loss with BMI less than 18 kg/ m2 occurred. Our preferred 92 
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method of ANS is ETF, but when ETF is not feasible or not tolerated by a patient, PN 93 
is recommended. PN is also recommended where there are overt signs of 94 
malabsorption of enteral nutrition e.g. intractable diarrhoea or vomiting. When 95 
indicated, ANS is introduced at a low rate and increase to tolerance over the first few 96 
days hence ANS of less than 4 days is considered unlikely to have been effective. 97 
In the current study, nutritional support between the date of hospital admission for 98 
HCT and the date of neutrophil engraftment (recovery) was reviewed and recorded 99 
for each patient. All patients with established ANS were classified as requiring either 100 
ETF, PN or both ETF and PN during some, or all of the time to engraftment. Patients 101 
that did not receive either modality, or received it for less than 4 days, were 102 
designated as having oral intake.  103 
During data collection it became apparent that, firstly there were low numbers of 104 
patients that successfully received enteral tube feeding, therefore oral intake and 105 
tube feeding patients were grouped together to form an enteral nutrition group. 106 
Secondly a number of patients defaulted to the “oral intake” group due to a lack of 107 
access or tolerance to ANS, rather than due to their ability to eat adequately. For the 108 
same reasons, some ANS episodes started late or terminated early. In order to 109 
isolate the effect of poor nutritional intake within each modality, overall nutritional 110 
intakes were categorised as either broadly adequate or clearly inadequate. For 111 
patients on oral intake alone, this was considered adequate unless there was a 112 
documented unmet need for ANS, according to our above stated criteria, for 4 or 113 
more days. ANS episodes were considered adequate if they started as planned and 114 
ended due to a successful transition to oral intake or an alternative method of 115 
support.  116 
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Using a combination of the route and adequacy of nutritional intakes, subjects were 117 
categorised into three nutrition groups: 1. Adequate enteral nutrition – patients 118 
who maintained an adequate nutritional intake either orally or those that also 119 
required 4 or more days of ETF. 2. Adequate parenteral nutrition – patients that 120 
achieved adequate nutritional intakes during the period that included 4 or more days 121 
of PN. 3. Inadequate nutrition - those with inadequate oral intake and a 122 
documented unmet need for ANS. 123 
Statistics 124 
Follow-up data were available on all patients. The main endpoints of the study were 125 
5 year survival,  GvHD-free/relapse-free survival (GRFS), NRM, defined as death 126 
without previous relapse/progression at 100 days after the date of hematopoietic cell 127 
infusion; incidence of acute GvHD at any site (grade II or above) and acute GvHD of 128 
the gut of any grade. Acute GvHD was graded according to standard criteria and 129 
events in GRFS included grade 3-4 acute GvHD, systemic therapy-requiring chronic 130 
GvHD, relapse, or death (12). All patients were considered assessable for acute 131 
GvHD after day +1 from the hematopoietic cell infusion, however, patients who did 132 
not survive to day 100 and did not have acute GvHD were excluded from the acute 133 
GvHD analyses.  Neutrophil engraftment was defined as absolute neutrophil count 134 
not lower than 1000/microL for 3 consecutive days. Route and adequacy of 135 
nutritional intake groups were compared using the Chi-squared or Mann-Whitney 136 
test as appropriate. The Kaplan-Meier method was used to produce survival and 137 
GFRS curves, with groups compared using with the log-rank test. Variables with P-138 
values <0.20 were entered into stepwise Cox-regression analyses to find the best 139 
models. Cumulative incidence curves for non-relapse mortality were constructed in 140 
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the competing risks framework considering relapse as the competing event. 141 
Differences between cumulative incidence curves were tested using the Gray 142 
method, and factors with P < .20 in univariate analysis, were entered into a 143 
multivariate regression analysis using the Fine and Gray model with a forward 144 
stepping procedure. Event data for grade 2–4 acute GvHD and gut acute GvHD 145 
were described as simple proportions, with groups compared using the Chi-squared 146 
test and logistic regression analysis with a forward stepping procedure being utilised 147 
to find independent prognostic factors. Statistical analyses were performed with IBM 148 
SPSS Statistics 24.0 and R version 3.2.2 (the CRAN project; www.cran.r-149 
project.org). Our pre-declared endpoints for this study were GvHD incidence and 150 
severity and early (transplant-related) mortality and survival. The decision to include 151 
5 year survival data was made post hoc. This is an accepted measure of cure within 152 
the HCT setting and was included to allow comparability with interventions in other 153 
studies. It must be noted that since not pre-specified, the 5-year analyses should be 154 
considered exploratory. All statistical tests were two sided, and P < .05 was used to 155 
indicate statistical significance. 156 
This study has not been registered as clinical trial. Participants were not 157 
prospectively allocated to an intervention hence criteria for registration was not met. 158 
Results 159 
Patient characteristics 160 
We identified 512 patients who met the inclusion criteria. We excluded 26 patients 161 
for whom there was no detailed information on nutritional support and a further 2 162 
patients who died within 3 days of transplantation in whom nutritional intake 163 
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adequacy could not be evaluated. The remaining 484 patients were included in the 164 
analyses. A total of 245 (51%) patients had adequate enteral nutrition (EN) either 165 
orally (N = 198) or with use of ETF (N = 47). Patients in whom ETF could not be 166 
established for the required time, received PN (N = 148, 31%) in order to provide 167 
adequate nutrition. The remaining 91 (19%) patients had inadequate nutrition due to 168 
either curtailed ANS (N = 33) or a failure to start ANS because of a lack of feeding 169 
access via any route (N = 58). Figure 1 indicates the route of intake for the study 170 
patients and their classification into nutritional group and Table 1 shows the exact 171 
length of feeding episodes between the dates of transplant and engraftment, 172 
categorised according to route and adequacy of nutritional intake.  173 
  174 
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Figure 1. Flow chart to determine the route and adequacy of nutritional intake 175 
between hematopoietic cell transplant and neutrophil engraftment. 176 
Subjects were categorised into three nutrition groups: 1. Adequate enteral nutrition 177 
(EN) – patients who maintained an adequate nutritional intake either orally or those 178 
that also required 4 or more days of enteral tube feeding (ETF). 2. Adequate 179 
parenteral nutrition (PN) – patients that achieved adequate nutritional intakes 180 
during the period that included 4 or more days of PN. 3. Inadequate nutrition - 181 
those with a documented unmet need for artificial nutrition support (ANS) for 4 or 182 
more days before engraftment. 183 
184 
  185 
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Table 1. Length of feeding episodes between transplant and neutrophil 186 













   Oral intake alone 
   With established ETF 






0 (0 – 3) 
12 (4 – 61) 
0 (0 – 61) 
 
0 (0 – 3) 
0 (0 – 3) 
0 (0 – 3) 
 
19  (7 – 42) 
20  (10 – 35) 
19  (7 - 42) 
Adequate PN: 
   With established PN 
   With established PN and ETF 






0 (0 – 3) 
7 (2 – 18) 
0 (0 – 18) 
 
16 (4 – 68) 
15  (4 – 22) 
16  (4 – 68) 
 
21  (11 – 38) 
23  (15 – 47) 
22  (11 – 47) 
Inadequate nutrition: 
   Oral intake alone 
   ETF given  
   PN given 
   ETF and PN given 








0 (0 – 3) 
7 (4 - 49) 
0 (0 – 3) 
16 (15 – 20) 
0 (0 – 49) 
lklklklklklklklkl 
0 (0 – 3) 
0 (0 – 3) 
8 (4 - 25) 
12 (5 – 37) 
0 (0 - 37) 
klklklklklklklklklkl 
21  (11 – 34) 
19  (12 – 30) 
22  (13 – 32) 
32  (30 – 36) 
21  (11 – 36) 
 188 
EN, enteral nutrition; ETF, enteral tube feeding; PN, parenteral nutrition. 189 
 190 
Overall, 285 (59%) of patients received myeloablative conditioning and 199 (41%) 191 
reduced intensity conditioning (RIC), as defined by the European Blood and Marrow 192 
Transplantation (EBMT) criteria (13). The characteristics of the study population, 193 
donors, and transplants according to nutritional group are summarised in Table 2. 194 
  195 
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Table 2. Patient and transplant characteristics according to category of 196 
nutritional route and adequacy 197 
 
Variable 
All (%) Adequate EN 
(%) 







All 484 245 (51) 148 (31) 91 (19) - 
Age group (years) 
Younger than 20 
20 to 40 
41 to 60 
























   Male 
















   Acute leukaemia 
   CML 
   Lymphoma & CLL 
   MDS & MPN 



























EBMT disease risk 
   Early 
   Intermediate 




















  Underweight (less than 20) 
  Healthy (20 – 24.9)  
  Overweight (25 – 30) 


























   Matched sibling 
   Matched unrelated 




















   Myeloablative 
















   No 
















Patient / Donor Sex 
   Other combination 
   Male / Female 



















Patient CMV serology 
   Positive 
   Negative 



















Donor CMV serology 
   Positive 
   Negative 

















   PBSC 
   BM 



















CD34+ cells infused 
   Less than 4.00 x 106  
   More than 3.99 x 106 






















   2000 – 2004 
   2005 – 2009 




















    0-1 
    2-3 
    More than 3 
























BM, bone marrow; CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia; CMV, 199 
cytomegalovirus; EBMT, European Blood and Marrow Transplantation Society; EN, enteral nutrition; 200 
HCT-CI, HCT comorbidity index; MDS, myelodysplastic syndromes; MPN, myeloproliferative 201 
neoplasms; PB, peripheral blood; PBSC, peripheral blood stem cells; PN, parenteral nutrition. 202 
 203 
Nutritional intake and non-relapse mortality 204 
The probability of NRM for the whole cohort was 14.7% (95% confidence interval 205 
(CI): 12  – 18). The effects of nutritional group on NRM were initially studied together 206 
with other patient, disease and transplant factors in univariate analyses; significant 207 
results of which are summarised in Supplementary Table 1.  208 
 209 
Subsequent multivariate analysis, showed significantly increased NRM in the 210 
adequate PN (HR 2.9; 95% confidence interval (CI) 1.6 – 5.4) and inadequate 211 
nutrition (HR 4.1; 95% CI 2.2 – 7.2) groups compared to those with adequate EN (all 212 
P < .001, Table 3, Figure 2(A)). HRs for NRM were also significantly associated with 213 
age, category 40-60 years (HR 1.9; 95% CI 1.1 – 3.1; P = .026) and > 60 years (HR 214 
3.1; 95% CI 1.5 – 6.8; P = .004) compared to those < 40 years old,  previous 215 
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autograft (HR 2.4; 95% CI 1.3 – 4.5; P = .007) and positive recipient cytomegalo 216 
virus (CMV) serology (HR 1.8; 95% CI 1.1 – 3.1; P = .028).  217 
 218 
Nutritional intake and acute GvHD  219 
There were 439 and 438 evaluable cases respectively for acute GvHD grade II or 220 
greater and gastrointestinal acute GvHD of any grade after exclusion of patients that 221 
died before day 100 without acute GvHD. Acute grade II or greater GvHD was 222 
observed in 179 (41%) patients and any gastrointestinal acute GvHD was 223 
documented in 153 (35%) patients. After univariate analyses (significant results 224 
summarised in Supplementary Table 1) the effects of nutritional intake were studied 225 
in multivariate analyses as summarised in Table 3: There were increased incidences 226 
of both acute GvHD ≥ grade 2 and gastrointestinal GvHD of any stage in patients 227 
who received PN (odds ratio (OR) 2.0; 95% CI 1.2 – 3.3; P = .006, and OR 1.8; 95% 228 
CI 1.1 – 3.0; P = .018, respectively), compared to adequate EN. Other significant 229 
covariates in the model for increased risk of both overall acute GvHD ≥ grade 2 and 230 
gut GvHD were the use of myeloablative conditioning versus RIC (OR 0.5; 95% CI 231 
0.3 – 0.7; P = .001 and OR 0.4; 95% CI 0.3 – 0.7; P < .001, respectively) and female 232 
donor to male recipient versus other combinations (OR 1.7; 95% CI 1.0 – 2.7; P = 233 
.047 and OR 1.8; 95% CI 1.1 – 3.0; P = .025, respectively).  234 
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Table 3. Factors significantly associated in multivariate analyses of NRM, acute GVHD, survival and GRFS 235 
 NRM at 100d 
(N = 479) 
Acute GvHD grade 2-4  
(N = 438) 
Gut acute GvHD any grade 
(N = 437) 
Survival at 5yrs 
(N = 454) 
GRFS at 5yrs 
(N = 454) 
N HR (95% CI) P N OR (95% CI)   P N OR (95% CI) P N HR (95%CI) P N HR (95%CI) P 
Nutritional intake group 
   Adequate EN 
   Adequate PN 







2.9 (1.6 – 5.4) 











2.0 (1.2 - 3.3) 











1.8 (1.1 - 3.0) 





























Recipient age (years) 
   Younger than 40 
   40-60 







1.9 (1.1 - 3.1) 
























   No 


























   Negative 


















Recipient / Donor Sex 
   Other combination 























   Myeloablative 
























EBMT Disease Risk 
   Early 
   Intermediate 
































    0-1 
    2-3 

































CI, confidence interval; CMV, cytomegalovirus; EBMT, European Blood and Marrow Transplantation; EN, enteral nutrition; GRFS, graft versus host disease-236 
free and relapse-free survival; GvHD, graft-versus-host disease; HCT-CI, hematopoietic cell transplant co-morbidity index; NRM, non-relapse mortality; NS, 237 
not statistically significant; PBSC, peripheral blood stem cells; PN, parenteral nutrition.238 
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Association of nutritional intake with survival and GRFS at 5 years 239 
The probability of survival at 5 years for the whole cohort was 49% (95% CI: 45 – 240 
54). Statistically significant factors associated with survival in univariate analyses are 241 
summarised in Supplementary Table 1. Multivariate analysis showed an increased 242 
risk of death in the adequate PN (HR 1.6; 95% CI 1.2 – 2.1, P = .003) and 243 
inadequate nutrition (HR 1.7; 95% CI 1.2 – 2.3. P = .003) groups compared to those 244 
with adequate EN (Table 3, Figure 2(B)) even when adjusted for other disease, 245 
patient and transplant factors.  246 
The probability of GRFS was 34% (95% CI: 30 – 38) and similarly to survival, 247 
multivariate analysis performed after univariate analysis (Supplementary Table 1) 248 
showed lower GRFS associated with the adequate PN (HR 1.6; 95% CI 1.3 – 2.1, P 249 
< .001) and inadequate nutrition (HR 1.6; 95% CI 1.2 – 2.1, P = .004) groups 250 
compared to adequate EN (Table 3, Figure 2(C)).  251 
 252 
Figure 2. Adjusted probabilities according to nutritional take group (from 253 
multivariate analyses shown in Table 3) of:  254 
(A) non-relapse mortality at 100 days after hematopoietic cell transplant (HCT); 255 
(B) 5-year survival after HCT; (C) 5-year graft versus host disease-free and 256 
relapse-free survival (GRFS) after HCT. Lines represent nutritional intake group; 257 
solid lines – inadequate nutrition, dotted lines – adequate parenteral nutrition, 258 
dashed lines – adequate enteral nutrition (EN) comprising oral intake and enteral 259 















To our knowledge, this is the largest report, with the longest follow up to date, on the 271 
role of nutrition on outcomes of allogeneic transplantation for hematologic 272 
malignancy and the first to include assessment of nutritional adequacy. Although the 273 
5-year analyses were post-hoc rather than pre-specified (and hence should be 274 
considered exploratory), data from this report potentially support two major 275 
conclusions. First, adequate EN during the early transplantation course was 276 
associated with reduced early mortality and improved survival and GRFS compared 277 
to adequate PN and inadequate nutrition. The probability of NRM for patients with 278 
adequate EN was 8.2% compared to 17.6% in those who received adequate PN and 279 
27.5 % in patients with inadequate nutrition. Second, in line with previous studies 280 
(14-18), EN was associated with a reduced risk of acute GvHD compared to PN. 281 
Grade II to IV GvHD was observed in 32% and gut GvHD in 27% of patients who 282 
received adequate EN compared to 55% and 48% respectively of patients with 283 
adequate PN. These data provide further evidence for the clinical relevance of ANS 284 
as a potentially modifiable risk factor for both early and 5 year mortality. 285 
Patients undergoing HCT struggle to consume an adequate diet at a time when 286 
requirements for nutrition are higher than usual and there is consensus that 287 
nutritional intakes should be optimised, including enteral and/or parenteral nutrition 288 
support where appropriate (19;20). These recommendations are supported by 289 
studies linking early mortality to nutritional status i.e. BMI recorded prior to HCT, 290 
although this may simply be a surrogate measure for disease severity (reviewed 291 
recently by Baumgartner et al, 2017) (21). More direct evidence in support of ANS 292 
has been missing.  Assessments of weight and BMI are confounded by fluid 293 
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accumulation, which is common in the early post-transplantation period. This can, 294 
particularly in patients who received PN, potentially overstate their nutritional status.  295 
A particular strength of our study is that we only used weight and BMI as parameters 296 
to identify the need for commencing ANS, whereas nutritional adequacy was 297 
assessed from the patient record. Any patient referred for oral or artificial nutritional 298 
support was under review by a specialist dietitian, hence inadequate intake by 299 
whatever route could be identified and be analysed separately from patients with 300 
good oral intake or effective ANS.  301 
It is well established that EN may serve therapeutic roles beyond providing metabolic 302 
substrates, due to its trophic effects on the gut mucosa hence benefits in terms of 303 
bacterial translocation, systemic infection and its ability to modulate the stress 304 
response. In addition there is also evidence of economic gains from EN (22). 305 
However, PN is still widely used after allogeneic HCT, due to relatively poor 306 
tolerance of ETF and because venous access is already established in these 307 
patients.  There are a few retrospective studies in HCT recipients that suggest 308 
superiority of EN over PN; for example, reductions in infections (23) and less early 309 
mortality and incidence of GvHD (16-18). More recent studies have retrospectively 310 
analysed outcomes of HCT cohorts where the patients were systematically offered 311 
ETF in preference to PN.  In these studies EN is associated with reduced duration of 312 
febrile neutropenia, faster neutrophil engraftment, reduced risk of acute GVHD and 313 
better survival at 100 days compared to PN (14;15;24).   314 
The relative advantage of EN could be explained by the known metabolic and other 315 
complications of PN. A pro-inflammatory effect of PN may also impact both NRM and 316 
GvHD (25;26). There are several plausible potential mechanisms for a beneficial 317 
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effect of EN on the maintenance of gut mucosal integrity and support of the GI tract 318 
environment, including cytokine production and host gut microflora. Gut associated 319 
lymphoid tissue plays an important role in the immune system. EN stimulates 320 
enterocyte turnover and supports the gut mucosal barrier and thus reduces 321 
translocation of bacteria and other inflammatory stimuli. Gut permeability changes as 322 
a result of changes to microbiota and strategies to modulate the gut microbiota after 323 
HCT are of increasing interest (27). Commensal bacteria are predominantly non-324 
pathogenic and have roles in immune regulation and maintenance of host barrier 325 
defence against pathogens. Short-term changes to the diet or PN infusion result in 326 
rapid and significant changes to the host microbiome and intestinal barrier function 327 
(3;28). 328 
Allogeneic HCT itself is accompanied by dramatic changes to the gut microbiota and 329 
there is increasing evidence that these changes to the microbiota may contribute to 330 
the development of post-transplant complications including GvHD (29). In keeping 331 
with the concept of gut nourishment we categorised patients with any PN episode of 332 
4 or more days into the PN group regardless of any other periods of tube feeding or 333 
oral intake. This ensured those patients with 4 or more days of an inadequately 334 
nourished gut (despite having adequate nutrition overall), were captured together. 335 
This is in contrast to other retrospective cohort studies where patients receiving both 336 
EN and PN were categorised into an enteral nutrition group.  337 
The obvious limitation of this study is its retrospective nature. We can only comment 338 
on associations without making causative links. Despite considering many known 339 
prognostic factors and performing multivariate analysis the nutritional support may 340 
only be a surrogate factor. For example, the inadequate nutrition group may 341 
represent more complex patients with severe gastrointestinal toxicity that prevented 342 
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enteral feeding, in combination with sepsis requiring removal of their central access 343 
jeopardising PN. Similar bias is possible when comparing EN and PN and will 344 
hopefully be resolved in an undergoing prospective randomised trial (30). 345 
In conclusion, our data show that adequate nutrition during the period to engraftment 346 
after allogeneic HCT is associated with improved NRM, survival and GRFS. 347 
Adequate EN is associated with significantly better results for these outcomes than 348 
adequate PN. Furthermore, adequate EN, predominantly via oral intake, may be 349 
associated with lower incidence of overall and gut acute GvHD when compared to 350 
PN, perhaps because of its ability to maintain gut mucosal integrity and for support of 351 
the gastrointestinal tract environment, including gut microflora.  352 
These data provide evidence for the clinical relevance of ANS as a potentially 353 
modifiable risk factor for outcomes of HCT. Although the retrospective and non-354 
randomised nature of this study can only indicate association, the improved survival 355 
and reduced incidence of acute GvHD that we identify, warrant further research into 356 
the potential benefits of enteral nutrition support in these patients.  357 
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Supplementary Table 1. Univariate analyses of factors on NRM, acute GvHD, survival and GRFS.  
Results shown where P < .2 
  
N 
NRM at 100d 
 % (95% CI) 
(N = 484) 
 
P 
Acute GvHD (%) 
(N = 439)  
 
P 
Gut acute GvHD (%) 
(N = 438)  
 
P 
Survival at 5 years 
 % (95%CI) 




GRFS at  5 years 
% (95%CI) 









Overall  14.7 (12-18) - 260 (59) 179 (41) - 285 (65) 153 (35) - 49 (45-54) - 34 (30-38) - 
Nutritional intake group 
   Adequate EN 
   Adequate PN 














































Recipient sex  
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Recipient age (years) 
   Younger than 40 
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   Other combination 
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Stem cell source 
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CD34 positive cell dose 
   Less than 4.0 x 106 
   More than 3.99 x 106 








































NRM at 100d 
 % (95% CI) 
(N = 484) 
 
P 
Acute GvHD (%) 
(N = 439)  
 
P 
Gut acute GvHD (%) 
(N = 438)  
 
P 
Survival at 5 years 
 % (95%CI) 




GRFS at  5 years 
% (95%CI) 
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EBMT disease risk 
   Early 
   Intermediate 
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    More than 3 
































BM, bone marrow; CI, confidence interval; CMV, cytomegalovirus; EBMT, European Blood and Marrow Transplantation; EN, enteral nutrition; GRFS, graft 
versus host disease-free and relapse-free survival; GvHD, graft-versus-host disease; HCT-CI, hematopoietic cell transplant co-morbidity index; NRM, non-
relapse mortality; NS, not statistically significant; PBSC, peripheral blood stem cells; PN, parenteral nutrition.
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